T2 Biosystems Announces Third Quarter 2024 Financial Results
14 nov. 2024 16h05 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024
05 nov. 2024 08h00 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today...
T2 Biosystems to Host Business Update Call on October 10, 2024
08 oct. 2024 16h05 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today...
T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform
08 oct. 2024 09h00 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass. and SCHENECTADY, N.Y., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance...
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
07 oct. 2024 09h05 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results
07 oct. 2024 09h00 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced...
T2 Biosystems Highlights New Article Published in The Lancet: Changing the Culture of Blood Culture
23 sept. 2024 09h00 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
20 sept. 2024 09h00 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
16 sept. 2024 09h00 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...
T2 Biosystems Provides Updates on its New Product Development Pipeline Progress
09 sept. 2024 09h00 HE
|
T2 Biosystems, Inc.
LEXINGTON, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,...